These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 15238591

  • 1. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, 'A to Z' Investigators.
    JAMA; 2004 Jul 07; 292(1):55-64. PubMed ID: 15238591
    [Abstract] [Full Text] [Related]

  • 2. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators.
    JAMA; 2004 Jul 07; 292(1):45-54. PubMed ID: 15238590
    [Abstract] [Full Text] [Related]

  • 3. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F, ACUTE II Investigators.
    Am Heart J; 2002 Sep 07; 144(3):470-7. PubMed ID: 12228784
    [Abstract] [Full Text] [Related]

  • 4. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M.
    J Invasive Cardiol; 2000 Dec 07; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [Abstract] [Full Text] [Related]

  • 5. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L, TETAMI Investigators.
    J Am Coll Cardiol; 2003 Oct 15; 42(8):1348-56. PubMed ID: 14563573
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M, Théroux P, Weber S, Laramée P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD.
    Int J Cardiol; 1999 Dec 01; 71(3):273-81. PubMed ID: 10636535
    [Abstract] [Full Text] [Related]

  • 7. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
    de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E, Investigators.
    Eur Heart J; 2004 Oct 01; 25(19):1688-94. PubMed ID: 15451146
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
    Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM.
    JAMA; 2004 Jul 07; 292(1):89-96. PubMed ID: 15238596
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
    N Engl J Med; 1998 May 21; 338(21):1488-97. PubMed ID: 9599103
    [Abstract] [Full Text] [Related]

  • 10. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct 21; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 11. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG, INTERACT Trial Long-Term Follow-Up Investigators.
    Am Heart J; 2006 Feb 21; 151(2):373-9. PubMed ID: 16442903
    [Abstract] [Full Text] [Related]

  • 12. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T, Theroux P, Snapinn S, Wan Y, Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca.
    Am Heart J; 2003 Oct 21; 146(4):668-73. PubMed ID: 14564321
    [Abstract] [Full Text] [Related]

  • 13. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E, TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators.
    N Engl J Med; 2001 Jun 21; 344(25):1879-87. PubMed ID: 11419424
    [Abstract] [Full Text] [Related]

  • 14. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr 21; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [Abstract] [Full Text] [Related]

  • 15. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
    Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A, Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators.
    Circulation; 2003 Jan 21; 107(2):238-44. PubMed ID: 12538422
    [Abstract] [Full Text] [Related]

  • 16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.
    N Engl J Med; 1998 May 21; 338(21):1498-505. PubMed ID: 9599104
    [Abstract] [Full Text] [Related]

  • 17. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS, Ottervanger JP, ten Berg JM, Gosselink AT, van Houwelingen G, Dambrink JH, Stella PR, Hamm C, van 't Hof AW, On-TIME 2 Trial Investigators.
    J Invasive Cardiol; 2012 Mar 21; 24(3):84-9. PubMed ID: 22388296
    [Abstract] [Full Text] [Related]

  • 18. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
    Goodman S.
    Am Heart J; 2005 Apr 21; 149(4 Suppl):S73-80. PubMed ID: 16124951
    [Abstract] [Full Text] [Related]

  • 19. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E, Cakmak M, Tartan Z, Cam N.
    Heart Vessels; 2003 Jul 21; 18(3):117-22. PubMed ID: 12955426
    [Abstract] [Full Text] [Related]

  • 20. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
    Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E.
    Am Heart J; 2001 Aug 21; 142(2):211-7. PubMed ID: 11479456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.